South East Clinical Senates

Independent, clinical and strategic advice for health systems in the south east

Biosimilar Medicines

(Advice to NHSE) To what extent and how should the transition to use of biosimilar medicines be prioritised to enable the provision of best value care in the NHS? Does the clinical Senate support the update of biosimilar medicines at pace and how can their best practice use be maximised?

Clinical Senate

South West

Status:

Complete

Date:

Dec-17

Types of Work:

Advice

Theme

Service optimisation

Policy / Documentation

No

Specialised Commissioning

yes

STP / ACS Development Plans

No

Urgent & Emergency Care

No

Multiple Clinical Services

No

Children & Maternity

No

Cardiac

No

Stroke & Vascular

No

Mental Health

No

Respiratory

No

MSK

No

ENT

No

Community Services/ Hubs

No

Diagnostics / Hubs

No

Primary Care

No

Public Health

No

Care Planning

No

Communications

No

Workforce

No

Link to web page or report

Uptake of Biosimilar Medicines in the South West – South West Senate